Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis
ConditionGastritis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19-75
SponsorDaewoong Pharmaceutical Co. LTD.
About this trial
This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.
Eligibility criteria
Qualifiers
Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.
Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
Subjects who present with at least one subjective symptom requiring medical treatment
Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.
Disqualifiers
Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
12,000 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov